Fibrinolytics.

Streptokinase

Powder in vials.

Infusion, streptokinase 250,000 units ; 750,000 units ; 1.5 million units .

Deep vein thrombosis, pulmonary embolism, acute arterial thromboembolism, acute myocardial infarction, clotted haemodialysis shunts.

Intravascular administration: initially 600,000 i.u. over 30 - 60 minutes, maintenance, 100, 000 i.u. hourly for 3 - 6 days. Acute M.I., 1 .5 million i.u. by intravenous infusion over 1 hour. Haemodialysis shunts.

Titrate initially; maintenance, 1300 - 1400 i.u./kg body-weight/ hour for 3 - 6 days. See data sheet. Not recommended in acute M.I.

Allergy to streptokinase, recent streptokinase therapy (5 days to 6 months previously), severe liver or kidney damage. Recent haemorrhage or CVA, fibrinolysis and uncontrolled bleeding disorders, haemorrhagic diathesis, severe hypertension, streptococcal infections, subacute bacterial endocarditis. Recent surgery, bleeding tendencies. Pregnancy.

Obtain haemostatic status of patient before starting therapy. Follow up with anticoagulant therapy; see data sheet. Haemorrhagic retinopathy.

Anticoagulants, drugs affecting platelet function.

Hypotension, arrhythmias. Febrile reactions, anaphylaxis (rare), polyneuropathy, uveitis. Haemorrhage.

Pharmacia & Upjohn

(POM)